2016年中国肿瘤免疫治疗研讨会

研讨会议题：

专题1基础免疫与癌症免疫

This session highlights the basicprinciples of immunology, provides a succinct and clear illustration of immuneresponses against cancer for busy clinicians.

重点讲述免疫学基本原则，为工作繁忙的临床医生提供简洁明了的抗癌免疫反应示例。

专题2细胞疗法的临床进展

The excitement in adoptive T cell therapy for malignancies will be showcased, including discussion on CAR-T cells,cytokine-activated killer cells and other forms of cellular therapy.

展示与讨论细胞治疗恶性肿瘤,包括关于CAR-T细胞, CIK和其他形式的细胞疗法。

专题3检查点抑制剂的临床进展

This session brings the most up to datedevelopments in the clinical applications of immune checkpointinhibitors against CTLA4 and PD1 pathway for  the treatment of lung cancer, melanoma,hematological malignancies, gastrointestinal cancers and genitourinary malignancies.应用免疫检查点抑制剂抗CTLA4 和PD1通路治疗肺癌、黑色素瘤、血液恶性肿瘤、胃肠道癌症和生殖泌尿系恶性肿瘤的临床最新进展。

专题4新型免疫疗法的出现

Novel forms of immunotherapy will beupdated including oncolytics, bispecific antibodies and cancer vaccines. Immunecheckpoint blockers against pathways other than CTLA4 and PD1 will bediscussed.

新型免疫疗法情况介绍，包括溶瘤、双特异性抗体和癌症疫苗，并就CTLA4和PD-1通路以外的免疫检查点阻断剂进行讨论。

专题5业界视角

This session will highlight the excitingimmune-oncology program from major pharmas including Merck, BMS,Roche/Genentech, AstraZeneca, Novartis, Merck Sereno/Pfizer, Amgen, BeiGene andHenri

重点介绍制药业界令人振奋的免疫肿瘤项目进展，包括默克、百时美施贵宝、罗氏/基因泰克、阿斯利康、诺华、默克雪兰诺、辉瑞、安进、百济神州和恒瑞。

专题6独特临床开发的思考

This session brings world expertstogether to discuss the unique clinical challenges in thedevelopment of cancer immunotherapeutics, including biomarker research,clinical trial design, combination therapy with targeted therapy or othermodalities such as radiation therapy.

探讨在癌症免疫治疗中所面临的临床挑战,包括生物标记物的研究、临床试验设计、与靶向治疗或放射治疗等其他治疗方法相结合的疗法。

专题7监管考量

Regulatory challenges in immune-oncologywill be discussed by experts from the Food and Drug Administration of the USA,the European Medicines Agency of the European Union, and the China Food andDrug Administration.

来自美国FDA、欧盟EMA以及CFDA的专家将一起探讨监管机构在免疫肿瘤领域所面临的挑战。